Researchers from the University of Illinois Urbana-Champaign have identified a protein that can predict which breast cancer patients will respond well to chemotherapy and immunotherapy. The study, which conducted genome-wide screening in human cancer cells, found that the FGD3 protein serves as a promising biomarker for determining treatment efficacy. This discovery could lead to more personalized treatment plans, sparing patients from ineffective therapies and their side effects.
The findings are particularly relevant for companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), which focuses on developing new immunotherapies targeting different kinds of cancer. By identifying patients who are likely to benefit from such treatments, the biomarker could enhance clinical trial design and patient outcomes.
According to the press release, the research team performed a genome-wide screen to identify proteins that influence how cancer cells respond to chemotherapy and immunotherapy. The FGD3 protein emerged as a key factor, with its expression levels correlating with treatment success. Patients with higher levels of FGD3 showed better responses to both types of therapy.
The implications of this study are significant for the field of oncology. Currently, many breast cancer patients undergo chemotherapy and immunotherapy without knowing if they will benefit. The FGD3 biomarker could help oncologists tailor treatments, potentially improving survival rates and quality of life. Additionally, the biomarker may aid in the development of new drugs that target the FGD3 pathway.
The research was conducted by scientists at the University of Illinois Urbana-Champaign, who published their findings in a peer-reviewed journal. The team plans to validate the biomarker in larger clinical trials before it can be widely adopted in clinical practice.
For investors and stakeholders in the biotech industry, this discovery highlights the potential for precision medicine in cancer treatment. Companies like Calidi Biotherapeutics, which are at the forefront of immunotherapy innovation, could benefit from incorporating such biomarkers into their drug development pipelines.
This news was disseminated by TinyGems, a communications platform focused on small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio @IBN, which provides access to a network of wire solutions, editorial syndication, press release enhancement, social media distribution, and corporate communications services.
